Heart artery procedure plus drugs may boost heart function in ischemic cardiomyopathy

NCT ID NCT06930092

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two approaches for people with ischemic cardiomyopathy (weak heart muscle due to blocked arteries) and multiple blocked vessels. One group gets optimal medical therapy alone, while the other also gets a heart artery procedure (PCI) guided by imaging and pressure measurements. The goal is to see if the combination better improves the heart's pumping ability. The trial plans to enroll 158 adults with a low ejection fraction (under 40%).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Percutaneous coronary intervention (PCI) with imaging guidance
What this could lead to: If successful, this could show that combining PCI with medication helps restore heart function more than medication alone in people with ischemic cardiomyopathy.
What could go wrong: This is a relatively small trial (158 participants) and not yet in a late phase. The benefits may be modest, and PCI carries risks like bleeding or vessel damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy dilated cardiomyopathy myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC CARDIOMYOPATHY

Contacts and locations

Locations

Seoul National University Hospital
RECRUITING

Seoul, Chongno-gu, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.